StockNews.com Initiates Coverage on Evogene (NASDAQ:EVGN)

StockNews.com started coverage on shares of Evogene (NASDAQ:EVGNFree Report) in a report issued on Monday morning. The firm issued a sell rating on the biotechnology company’s stock.

Separately, Lake Street Capital dropped their target price on shares of Evogene from $30.00 to $12.00 and set a “buy” rating for the company in a research report on Friday, August 23rd.

Get Our Latest Research Report on Evogene

Evogene Stock Performance

Shares of EVGN stock opened at $1.68 on Monday. The company has a market capitalization of $9.02 million, a PE ratio of -0.44 and a beta of 1.43. Evogene has a 52-week low of $1.66 and a 52-week high of $10.40. The business’s fifty day moving average is $2.49 and its 200 day moving average is $4.59.

Evogene (NASDAQ:EVGNGet Free Report) last released its quarterly earnings results on Thursday, August 22nd. The biotechnology company reported ($1.06) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.94). The business had revenue of $0.91 million during the quarter. Evogene had a negative net margin of 210.26% and a negative return on equity of 72.33%.

Institutional Investors Weigh In On Evogene

A hedge fund recently bought a new stake in Evogene stock. Renaissance Investment Group LLC acquired a new stake in shares of Evogene Ltd. (NASDAQ:EVGNFree Report) during the 3rd quarter, according to its most recent filing with the SEC. The institutional investor acquired 10,000 shares of the biotechnology company’s stock, valued at approximately $31,000. 10.40% of the stock is owned by hedge funds and other institutional investors.

About Evogene

(Get Free Report)

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.

Featured Stories

Receive News & Ratings for Evogene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evogene and related companies with MarketBeat.com's FREE daily email newsletter.